Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
News Briefing channel feed
Mustang Bio to lay off workers; MaaT's new data for microbiome therapy
Last year
Nurix's $175M offering; Invivyd CEO is out
Last year
Century Therapeutics buys Clade; Eliem announces $120M PIPE and a deal
Last year
Skye Bioscience uplists; OncoX's licensing deal with ABVC BioPharma
Last year
Acrivon draws in $130M; Vincerx Pharma's Ph1 metastatic tumor data
Last year
LIB details Ph3 PCSK9 inhibitor data; Eyenovia seeks 'strategic alternatives'
Last year
Protara's $45M placement; Plus, news about Eupraxia and GenSight
Last year
Candel’s promising Ph2 data in pancreatic cancer; Microbiome biotech raises £27M
Last year
Ascletis Pharma scraps liver disease program; Another reverse merger
Last year
Zymeworks removes CFO; Gilead extends Nurix deal
Last year
Omega cuts 35% of workforce; Rhythm, CervoMed, Surrozen raise new funding
Last year
Bayer to cut 90 workers; Avalo's up to $185M private placement
Last year
Gamida Cell to go private; Stoke aims to raise $75M
Last year
Edgewood's $20M Series A; Nanoscope to pursue FDA approval for eye gene therapy later this year
Last year
Axsome clears Phase 3 in narcolepsy; Nkarta eyes $240M raise
Last year
Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise
Last year
Innate ends Ph1b in peripheral T cell lymphoma; Layoffs at NextCure
Last year
AbbVie inks deal with Parvus; Sofinnova invests in Cure51
Last year
Madrigal's $600M offering; PureTech to return $100M to shareholders
Last year
Bluebird's $175M loan; Spyre reveals second private placement
Last year
Biotheus builds on ADC pact with Hansoh; Novartis expands in Singapore; Astellas leaves Cartesian deal
Last year
OcuTerra’s diabetic retinopathy drug fails PhII; Better Therapeutics to shut down
Last year
Takeda's PhII mezagitamab data; Apogee's $483M raise; Galderma's IPO
Last year
Regulus raises $100M; Cancer company files to go public
Last year
First page
Previous page
8
9
10
11
12
13
14
Next page
Last page